Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies

Brain

Volumn 131, Issue 5, 2008, Pages 1168-1170

  Lehmann, Helmar C ^a   Hartung, Hans Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC NEUROPATHY; AUTOIMMUNITY; BODY PLETHYSMOGRAPH; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; DRUG MECHANISM; ENTERITIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; NOTE; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; ANIMAL; COMPLEMENT ACTIVATION; DISEASE MODEL; IMMUNOLOGY; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MILLER FISHER SYNDROME; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL;

EID: 44949234808     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn072     Document Type: Note

References (40)

1. Allegretti M, Moriconi A, Beccari AR, Di Bitondo RR, Bizzarri C, Bertini R, et al. Targeting C5a: Recent advances in drug discovery. Curr Med Chem 2005; 12: 217-36.
2. Atkinson C, Qiao F, Song H, Gilkeson OS, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease inMRL/lprmice. J Immunol 2008; 180: 1231-8.
3. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993; 43: 1911-7.
4. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997; 745: 32-6.
5. Feasby TE, Gilbert JJ, Hahn AF, Neilson M. Complement depletion suppresses Lewis rat experimental allergic neuritis. Brain Res 1987; 419: 97-103.
6. Fisher M. An unusual variant of acute idiopathic polyneuritis (Syndrome of ophthalmoplegia, ataxia, areflexia). N Engl J Med 1956; 255: 57-65.
7. Goodfellow JA, Bowes T, Sheikh K, Odaka M, Halstead SK, Humphreys PD, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci 2005; 25: 1620-8.
8. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999; 104: 697-708.
9. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996a; 40: 635-44.
10. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996b; 39: 625-35.
11. Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RA, Willison HJ. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol 2005; 58: 203-10.
12. Halstead SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, Jacobs BC, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008.
13. Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV. Guillain-Barre syndrome: activated complement components C3a and C5a in CSF. Neurology 1987; 37: 1006-9.
14. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-43.
15. Houliston RS, Yuki N, Hirama T, Khieu NH, Brisson J-R, Gilbert M, et al. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barre and Fisher syndromes. Biochemistry 2007; 46: 36-44.
16. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005; 366: 1653-66.
17. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003; 126: 2220-34.
18. Jung S, Toyka KV, Hartung HP. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 1995; 200: 167-70.
19. Kaida K, Kanzaki M, Morita D, Kamakura K, Motyoshi K, Hirakawa M, et al. Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2006; 77: 1043-6.
20. Kanzaki M, Kaida K, Ueda M, Morita D, Hirakawa M, Motoyoshi K, et al. Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry. Available at: www.jnnp.bmj.com. Accessed 13 March, 2008.
21. Kieseier BC, Hartung H-P, Wiendl H. Immune circuitry in the peripheral nervous system. Curr Opin Neurol 2006; 19: 437-45.
22. Koga M, Gilbert M, Li J, Koike S, Takahashi M, Furakawa K, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005; 64: 1605-11.
23. Koski CL, Sanders ME, Swoveland PT, Lawley TJ, Shin ML, Frank MM, et al. Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J Clin Invest 1987; 80: 1492-7.
24. Lehmann HC, Hartung H-P, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders. Part 2 Treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066-71.
25. Lo YL. Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve 2007; 36: 615-27.
26. Markiewski MM, Lambris JD. Biological perspectives. The role of complement in inflammatory diseases: from behind the scenes into the spotlight. Am J Pathol 2007; 171: 715-27.
27. Meyer zu Hörste G, Hartung H-P, Kieseier BC. From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007; 3: 198-211.
28. Mollnes TE, Kirschfink M. Strategies of therapeutic complement inhibition. Mol Immunol 2006; 43: 107-21.
29. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guiillain-Barre syndrome. Arch Neurol 2007; 64: 1519-23.
30. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison J, Wagner ER, Goodyear CS, et al. Anti-GQ1b antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 2001; 124: 893-906.
31. Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders (Review). The Cochrane Library 2007; 2: 1-14.
32. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
33. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25: 1265-75.
34. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007; 27: 3956-67.
35. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. The Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326: 1123-9.
36. Vriesendorp FJ, Flynn RE, Pappolla MA, Koski CL. Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J Neuroimmunol 1995; 58: 157-65.
37. Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995; 92: 8955-9.
38. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125: 2591-625.
39. Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007; 35: 691-711.
40. Zhang G, Lopez PH, Li CY, Mehta NR, Griffin JW, Schnaar RL, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004; 127: 1085-100.